AvantGen: AvantGen Receives an Award from the NIH/RADx to Commercialize its Anti-SARS-CoV-2 Nucleocapsid Antibodies for Ultra-high Sensitivity Lateral Flow Assay Development

SAN DIEGO, May 25 (Korea Bizwire) - AvantGen, a San Diego-based biotech, is a leader in the use of yeast display technology for human and rabbit monoclonal antibody discovery and optimization. AvantGen has received an award from the NIH's RADx Next program to expedite the commercialization of its high affinity rabbit monoclonal antibodies against the nucleocapsid [...]The post AvantGen Receives an Award from the NIH/RADx to Commercialize its Anti-SARS-CoV-2 Nucleocapsid Antibodies for Ultra-high Sensitivity Lateral Flow Assay Development appeared first on Be Korea-savvy.